Xcout IntelPrime Medicine, Inc.
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Subscribe to see Prime Medicine, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Prime Medicine, Inc. at a glance
Prime Medicine, Inc. is a biotechnology company headquartered in Cambridge, United States. It is publicly listed (PRME) with a market capitalisation of $652M. Xcout tracks 27 named people at Prime Medicine, Inc., including Allan Reine (Chief Executive Officer & Director). Xcout recorded 16 job postings from Prime Medicine, Inc. in the last 90 days, naming tools such as LangChain, LangGraph.
Prime Medicine, Inc. leadership
- Allan ReineChief Executive Officer & Director
- Svetlana MakhniChief Financial Officer
- Ann L. LeeChief Technical Officer
- Ann LeeChief Technical Officer
- Matthew J. HawrylukChief Business Officer
- Matthew HawrylukChief Business Officer
21 more named people on record for Prime Medicine, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Prime Medicine, Inc.
Xcout recorded 16 job postings from Prime Medicine, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Prime Medicine, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Prime Medicine, Inc.'s hiring signals →
Tech stack
Prime Medicine, Inc. competitors
A few of Prime Medicine, Inc.'s closest competitors — see the full list of competitors and alternatives →
Verve Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, dedicated to pioneering single-course gene editing medicines for cardiovascular disease.
KOMO Biosciences is a biotechnology research company headquartered in Cambridge, Massachusetts. The company specializes in next-generation precision genome engineering driven by highly efficient, evolved integrases.
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Get Prime Medicine, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Prime Medicine, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Prime Medicine, Inc. in Xcout Intel
- 27 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access